When US health officials meet next month to reconsider a list of controversial peptide drugs, they will hear from a new set of voices: doctors and pharmacists with deep financial ties to the burgeoning industry of unproven chemicals.
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: CNN (@cnn.com)
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: CNN (@cnn.com)